ABUS Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
299.0K
-70.5%
1.0M
-99.4%
179.1M
+16943.4%
1.1M
+98.7%
529.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
299.0K
-70.5%
1.0M
-99.4%
179.1M
+16943.4%
1.1M
+98.7%
529.0K
Operating Expenses
10.8M
+54.7%
7.0M
-31.7%
10.2M
+61.1%
6.3M
-31.0%
9.2M
R&D
2.6M
-9.7%
2.9M
-29.7%
4.1M
-17.7%
5.0M
-13.4%
5.8M
SG&A
8.0M
+105.7%
3.9M
-34.3%
5.9M
+59.6%
3.7M
+21.2%
3.0M
Operating Income
-10494000
-76.0%
-5964000
-103.5%
168.9M
+3293.0%
-5290000
+38.9%
-8659000
EBITDA
-10484000
-76.1%
-5953000
-103.5%
168.9M
+3494.7%
-4976000
+41.8%
-8550000
Net Income
59.1M
+1238.6%
-5192000
-103.1%
169.7M
+4618.0%
-3756000
+51.5%
-7742000
EPS (Basic)
$0.30
+1100.0%
$-0.03
-103.4%
$0.88
+4500.0%
$-0.02
+50.0%
$-0.04
EPS (Diluted)
$0.30
+1100.0%
$-0.03
-103.4%
$0.87
+4450.0%
$-0.02
+50.0%
$-0.04
Shares (Diluted)
199.6M
+1.1%
197.5M
+1.2%
195.2M
+1.9%
191.5M
-0.1%
191.8M
Arbutus Biopharma (ABUS) — Financials